Monitor the outcome of the securities class action appeal filed September 30, 2026 — reinstatement would reintroduce litigation overhang. Also watch for any shareholder dissent on say-on-pay given the company's sustained net losses and CEO compensation of $1.19M. The auditor ratification is routine but note CBIZ is being acquired by Grant Thornton — a change in auditor could follow.
Price Chart
Executive Summary
Actinium Pharmaceuticals filed its definitive proxy statement for the 2026 Annual Meeting, seeking to re-elect directors David Nicholson and Richard I. Steinhart, ratify CBIZ CPAs P.C. as auditor, and hold an advisory say-on-pay vote. The filing discloses CEO Sandesh Seth's 2025 total compensation of $1,187,320 (salary $762,320 + bonus $425,000) and former CFO Steve O'Loughlin's $546,437. The company reported a net loss of $33.9M in 2025 and has an ongoing securities class action appeal after the complaint was dismissed with prejudice. The proxy is routine governance material with no shareholder proposals or contested elections.
Key Facts
- Annual Meeting scheduled for November 25, 2026; record date October 2, 2026 with 31,441,436 shares outstanding
- Proposals: elect Class I directors Nicholson and Steinhart, ratify CBIZ as auditor, advisory say-on-pay vote
- CEO Sandesh Seth 2025 total compensation: $1,187,320 ($762,320 salary + $425,000 bonus)
- Former CFO Steve O'Loughlin 2025 total compensation: $546,437 ($445,536 salary + $100,901 bonus)
- Net loss for 2025: $33,887,000 (improved from $38,243,000 in 2024 and $48,818,000 in 2023)
- TSR on $100 investment: $47.70 in 2025 vs $11.83 in 2024
- Securities class action dismissed with prejudice on September 4, 2026; plaintiffs filed notice of appeal on September 30, 2026
- On March 31, 2025, Board approved cancellation of stock options for 4.9M shares; Seth cancelled 2,385,974 options, O'Loughlin cancelled 703,255
- On September 2, 2026, Seth granted option for 1,130,400 shares and 1,762,874 RSUs; non-employee directors granted options and RSUs
- All directors and officers as a group beneficially own less than 1% of outstanding shares (284,923 shares)
Financial Impact
CEO compensation of $1.19M and net loss of $33.9M in 2025; no material financial impact from proxy items
Risk Factors
- Pending appeal of securities class action dismissal creates litigation uncertainty
- Sustained net losses ($33.9M in 2025) with no approved products or revenue stream disclosed
- CEO compensation of $1.19M against $33.9M net loss may attract say-on-pay opposition
- Auditor transition risk if CBIZ acquisition by Grant Thornton closes and firm status changes
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-110022 |
| Document: 0001213900-26-110022-index-headers.html | 0001213900-26-110022 |
| Document: 0001213900-26-110022-index.html | 0001213900-26-110022 |
| Document: 0001213900-26-110022.txt | 0001213900-26-110022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | DEF 14A | $1.13 | awaiting T+20 | — | $1.42 (+25.66%) |
Oct 15, 2026 11d ago | 8-K | $1.13 | awaiting T+20 | — | $1.42 (+25.66%) |
Aug 14, 2026 10w ago | Press Release | $1.05 $1.25 | ▲ +19.05% | ▲ +21.03% | $1.42 (+35.24%) |
Aug 14, 2026 10w ago | 8-K | $1.05 $1.25 | ▼ −19.05% | ▼ −21.03% | $1.42 (−35.24%) |
Jun 18, 2026 18w ago | 8-K | $1.03 $0.9219 | ▲ +10.50% | ▲ +10.35% | $1.42 (−37.86%) |
May 29, 2026 21w ago | 8-K | $1.18 $0.9800 | ▲ +16.95% | ▲ +15.65% | $1.42 (−20.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers